Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn about a paper he co-authored with colleagues published in Blood:
“Congratulations to Taylor R. Brooks and Brian T. Hill for teaming up 21 hospitals (including Mount Sinai) for the largest real-world series of Glofitamab and Epcoritamab efficacy in aggressive lymphoma bispecifics.”
Title: Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Authors: Taylor R. Brooks, Emily C. Zabor, Yohanna B. Bedelu, Xi Yang, Yasmin H. Karimi, Adrienne N. Nedved, Yucai Wang, Nikita Dave, Daniel J. Landsburg, Kelsey Baron, Boyu Hu, Daniel C. Trotier, Priyanka A. Pophali, Jordan Miller, Natalie Grover, Catherine Reinert, Ajay Major, Tenley Schwarz, Krish Patel, Kiarash Salafian, Emily Ayers, Suchitra Sundaram, Joshua D. Brody, Marshall McKenna, Yun Kyoung Ryu Tiger, Megan Sears-Smith, Nilanjan Ghosh, Chelsea Peterson, Cyrus Khan, Sean P. Bliven, Mayur Narkhede, Alyssa Gibson, Justin Kline, Javier Munoz, Rodolfo Garza-Morales, Carrie I. Ho, Stephen D. Smith, Alex Niu, Francisco Hernandez-Ilizaliturri, Fadzai Chinyengetere, Sandeep Dave, Nayef Abdel-Razeq, Muhamad Alhaj Moustafa, Paolo F. Caimi, Brian T. Hill.
Read the full article in Blood.
More posts featuring Joshua Brody.